Literature Review: Exosomes vs. Whole-Cell MSC Dynamics in Neural and Vascular Regeneration

Published: October 2026 | Category: Neurological and Vascular Research

Reviewed Evidence

Reviewed Study 1: Safety and Potential Effects of Intrathecal Injection of Allogeneic Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in Complete Subacute Spinal Cord Injury: A First-in-Human, Single-Arm, Open-Label Phase I Clinical Trial

Authors: Akhlaghpasand M, Tavanaei R, Hosseinpoor M, et al.

Publication and Date: Stem Cell Research & Therapy. 2024;15:264.

DOI/Link: https://doi.org/10.1186/s13287-024-03868-0 | PubMed

Reviewed Study 2: Circulating Extracellular Vesicles in Stroke Patients Treated With Mesenchymal Stem Cells: A Biomarker Analysis of a Randomized Trial

Authors: Bang OY, Kim EH, Cho YH, et al.

Publication and Date: Stroke. 2022;53(7):2276–2286.

DOI/Link: https://doi.org/10.1161/STROKEAHA.121.036545 | PubMed

Reviewed Study 3: Functional Outcome and Histologic Analysis of Late-Onset Total Type Brachial Plexus Injury Treated With Intercostal Nerve Transfer to Median Nerve With Local Umbilical Cord-Derived Mesenchymal Stem Cells or Secretome Injection: A Double-Blinded, Randomized Controlled Study

Authors: Widodo W, Dilogo IH, Kamal AF, et al.

Publication and Date: European Journal of Orthopaedic Surgery & Traumatology. 2024;34(8):4073–4082.

DOI/Link: https://doi.org/10.1007/s00590-024-04110-6 | PubMed

Reviewed Study 4: Extracellular Vesicles Can Deliver Anti-Inflammatory and Anti-Scarring Activities of Mesenchymal Stromal Cells After Spinal Cord Injury

Authors: Romanelli P, Bieler LS, Scharler C, et al.

Publication and Date: Frontiers in Neurology. 2019;10:1225.

DOI/Link: https://doi.org/10.3389/fneur.2019.01225 | PubMed

Supporting Publications

Supporting Publication 1: Extracellular Vesicles Improve Post-Stroke Neuroregeneration and Prevent Postischemic Immunosuppression

Authors: Doeppner TR, Herz J, Görgens A, et al.

Publication and Date: Stem Cells Translational Medicine. 2015;4(10):1131–1143.

DOI/Link: https://doi.org/10.5966/sctm.2015-0078 | PubMed

Supporting Publication 2: Exosomes Secreted by Human-Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Attenuate Limb Ischemia by Promoting Angiogenesis in Mice

Authors: Hu GW, Li Q, Niu X, et al.

Publication and Date: Stem Cell Research & Therapy. 2015;6:10.

DOI/Link: https://doi.org/10.1186/scrt546 | PubMed

Scientific Review By: Michael Healey, M.Ed., C.A.S.

Executive Summary and Key Takeaways

Primary Objective: Compare MSC-derived exosomes and other extracellular-vesicle products with whole-cell MSC therapies, focusing on biological differences, safety, delivery, signaling efficiency, and neural and vascular outcomes.

Products Evaluated: The evidence includes autologous and allogeneic MSCs, MSC-derived extracellular vesicles, products described as exosomes, and the broader MSC secretome. These products are related but are not interchangeable.

Key Finding: Animal studies show that MSC-derived extracellular vesicles can reproduce several anti-inflammatory, blood-vessel-forming, and neuroprotective effects of parental MSCs. Human evidence remains limited to small early studies and biomarker analyses.

Safety and Tolerability: Cell-free products avoid administering living cells, but current trials do not establish that exosomes are safer, equivalent, or superior to MSCs. Product source, manufacturing, purity, cargo, dose, storage, and delivery remain important safety variables.

Study Overview and Clinical Objectives

Current clinical evidence does not establish that exosomes are safer or more effective than whole-cell MSCs for neural or vascular regeneration. This review evaluates whether cell-free extracellular-vesicle products can reproduce MSC effects and whether human outcomes support a meaningful clinical difference.

Six publications were assessed. Human evidence included a nine-patient, single-arm, open-label Phase I trial designed primarily to assess initial treatment safety of intrathecal umbilical-cord MSC-derived exosomes for complete subacute spinal cord injury; a randomized chronic-stroke study of 39 autologous MSC recipients and 15 controls with extracellular-vesicle biomarker analysis; and a 15-patient randomized comparison of umbilical-cord MSCs and MSC secretome administered during nerve-transfer surgery.

Preclinical evidence included direct MSC-versus-extracellular-vesicle comparisons in rat spinal cord injury and mouse stroke, plus an exosome study in mouse hindlimb ischemia. Outcomes included inflammation, nerve recovery, scarring, blood-vessel growth, blood flow, and functional improvement.

Because the disease models, products, doses, delivery routes, comparison groups, outcomes, and follow-up periods differed, the findings were not pooled. Controlled human comparisons received the greatest weight, followed by uncontrolled safety evidence and mechanistic animal studies. Biomarker associations were treated as early signals rather than proof that isolated extracellular vesicles reproduce whole-cell treatment.

Biological Mechanism and Science

MSCs are living cells that can respond to changes in their environment. Rather than permanently replacing damaged neurons, support cells, or blood vessels, many proposed MSC effects are attributed to paracrine signaling. This means that MSCs detect injury signals and release substances that influence nearby immune, neural, and vascular cells.

The MSC secretome includes soluble cytokines, chemokines, growth factors, lipids, and extracellular vesicles. Extracellular vesicles are membrane-enclosed particles that may transport proteins, lipids, messenger RNA, microRNAs, and other regulatory cargo. Exosomes are one type of extracellular vesicle produced through a specific pathway inside the cell. A secretome product is broader and may contain both vesicles and soluble substances.

Unless a vesicle’s origin has been demonstrated, “extracellular vesicle” is generally more precise than “exosome.”

Extracellular vesicles may bind to surface receptors, fuse with cell membranes, or enter cells. Their cargo can affect inflammatory cytokines, microglial activity, nerve-cell survival, programmed cell death, scar formation, endothelial-cell growth, blood-vessel formation, and barrier function. MicroRNAs may change gene activity in recipient cells, but their effects depend on the source cells and manufacturing conditions.

Whole MSCs may adjust their signaling after administration, whereas an extracellular-vesicle product delivers cargo produced before treatment. This creates an important tradeoff. Living cells may adapt to changing injury signals, while vesicles may be easier to characterize, store, engineer, and administer repeatedly.

In Bang’s human stroke study, circulating extracellular vesicles increased approximately fivefold within 24 hours of autologous MSC infusion. Vesicle number remained associated with motor improvement after adjustment for age, sex, baseline stroke severity, and treatment timing. This supports vesicle release as a possible MSC mechanism, but it does not prove that the vesicles caused the improvement or that a manufactured vesicle product would reproduce the cells’ effects.

Cell-free also does not mean non-immunogenic. Vesicle membranes and cargo may interact with immune and blood-clotting pathways. “Lower immunogenic potential” is more accurate, and each product requires individual testing.

Key Findings and Neurological and Vascular Outcomes

Akhlaghpasand and colleagues evaluated nine patients with complete subacute spinal cord injury who received an intrathecal dose containing 300 µg of umbilical-cord MSC-derived exosomal protein and were followed for 12 months. Seven adverse events occurred in five patients, but none was judged attributable to the injection. Sensory, independence, and bowel-function measures improved from baseline. Four patients showed motor-score improvement, although the mean motor change was not statistically significant. Without a control group, concurrent spinal decompression and fixation, structured rehabilitation, and possible spontaneous recovery limit interpretation. This Phase I study supports feasibility but does not establish efficacy or comparative safety.

Bang and colleagues studied 39 chronic-stroke patients who received intravenous autologous MSCs and 15 who received standard care. Circulating extracellular vesicles increased about fivefold within 24 hours, and higher vesicle numbers were independently associated with motor improvement after adjustment for relevant clinical factors. Because isolated vesicles were not administered, this result supports a possible paracrine mechanism rather than equivalence between MSCs and manufactured vesicle products.

Widodo and colleagues compared local umbilical-cord MSCs in seven patients with MSC secretome in eight patients undergoing intercostal nerve transfer for late total brachial plexus injury. The MSC group improved more on the SF-36 health-change measure, while tissue measures of inflammation, regeneration, and fibrosis did not differ significantly. Surgery and rehabilitation affected both groups, and secretome is not the same as purified exosomes. The study therefore does not establish that either product is superior.

Romanelli and colleagues directly compared vehicle, MSCs, parental-cell extracellular vesicles, and sham surgery in rats with spinal cord contusion. MSCs and vesicles similarly reduced Iba1-positive microglia and macrophage accumulation by approximately 25% to 30%. Vesicles were more effective than parental MSCs in the study’s anti-scarring analysis. Most intravenously administered MSCs accumulated in the lungs. These results support paracrine activity in rats but do not establish comparative clinical effectiveness.

Doeppner and colleagues compared MSCs and their extracellular vesicles in a mouse ischemic-stroke model with 12 mice per condition. MSCs were administered on day 1, while vesicles were administered on days 1, 3, and 5. Through 28 days, vesicles reproduced parental-cell effects on neurological recovery, new neuron growth, blood-vessel formation, and immune regulation. Because the schedules differed, this was not a like-for-like comparison of potency per dose. The findings could mean that vesicles require repeated administration or that easier redosing is an advantage of the cell-free approach.

Hu and colleagues studied three groups of 20 mice: exosome treatment, control medium, and sham surgery. After femoral-artery excision, treated mice received 200 µg of exosomal protein derived from induced-pluripotent-stem-cell MSCs. At day 21, limb salvage was 65% versus 10% in controls, with improved blood flow and small blood-vessel density. The study supports blood-vessel-forming activity but did not compare exosomes directly with MSCs or establish benefit in people.

Clinical Data Summary

Stemedix Clinical Context

The evidence supports continued investigation of MSC-derived extracellular vesicles, not treatment certainty. Exosomes may avoid cell clumping, division, differentiation, unintended persistence, and some lung trapping associated with living-cell administration. However, the nine-patient spinal-cord study cannot detect uncommon harms or show a lower adverse-event rate than MSC treatment. Seven adverse events occurred in five participants, although none was attributed to the product.

Extracellular vesicles create different uncertainties. Their cargo depends on donor cells, culture conditions, isolation, purification, and storage. A product may contain desired anti-inflammatory or blood-vessel-forming signals alongside unwanted inflammatory, fibrotic, blood-clotting, or growth-related molecules. Particle count alone does not establish identity, purity, potency, or dose consistency.

The delivery route also changes risk and where the product travels. Intravenous products may be rapidly taken up by the liver, spleen, and lungs. Intrathecal delivery places material closer to the spinal cord but requires an invasive procedure. Results from local intramuscular injections in mice cannot be generalized to systemic neurological or vascular treatment.

The studies support extracellular vesicles as one part of MSC paracrine signaling. Bang linked MSC infusion with a rapid rise in circulating vesicles. Romanelli found that vesicles reproduced several parental-cell effects and exceeded the cells’ anti-scarring effect in one rat analysis. Doeppner also reported similar cell and vesicle effects in mice, but the vesicles were given three times and the cells only once. This could indicate lower potency per administration or a practical advantage from easier repeat dosing.

Living MSCs can continue sensing and responding to their environment, while an extracellular-vesicle preparation carries fixed cargo. Neither approach has been shown to be superior in an adequately powered human trial.

Patient selection may also affect apparent response, but the reviewed studies were too small or were not designed to identify reliable responder profiles. Future trials should directly compare standardized extracellular-vesicle products with their parental MSCs using matched patient groups, delivery routes, dosing schedules, outcomes, and follow-up. Manufacturing, purity, potency, distribution, durability, functional outcomes, and long-term adverse events should be reported consistently.

Frequently Asked Questions

What are the main biological differences between exosomes and MSCs?

MSCs are living cells that respond to tissue signals and continue releasing biological factors. Exosomes are nonliving extracellular vesicles carrying preformed proteins, lipids, and regulatory RNA. They cannot divide or differentiate, but their cargo can influence immune, neural, and vascular cells.

Are exosomes safer than whole-cell stem cell therapy?

They may avoid some risks associated with living cells, but comparative human safety has not been established. Safety depends on the source cells, cargo, purity, manufacturing, dose, storage, and delivery route. The nine-patient spinal-cord study found no adverse event attributable to treatment but was too small to detect uncommon harms.

How does extracellular-vesicle signaling differ from cell replacement?

Cell replacement aims to replace damaged cells. MSC research increasingly emphasizes paracrine signaling, in which cells release factors that alter the recipient’s existing immune, neural, and vascular responses. Extracellular-vesicle therapy attempts to deliver part of that signaling system without administering intact cells.

What is the difference between exosomes and the MSC secretome?

Exosomes are one type of extracellular vesicle. The secretome includes extracellular vesicles plus soluble cytokines, chemokines, growth factors, lipids, and other substances released by cells. A secretome study should not be described as a purified exosome trial.

Do clinical trials show that exosomes work better than MSCs?

No. Direct human comparisons are extremely limited. The 15-patient Widodo study compared MSCs with broader secretomes during nerve-transfer surgery, not purified exosomes, and did not establish superiority. Most direct MSC-versus-extracellular-vesicle evidence remains preclinical.

Can MSC-derived exosomes promote neural or vascular repair?

Animal studies report reduced inflammation and scarring, increased new neuron and blood-vessel growth, and improved blood flow or functional measures. These findings support biological plausibility, but the products and models vary, and human effectiveness has not been established.

Regulatory Disclaimer

This review is provided by Stemedix for educational and informational purposes only and represents an academic commentary on published literature. The featured studies evaluate experimental procedures. Regenerative cell therapies and extracellular-vesicle therapies discussed are not FDA approved for spinal cord injury, stroke, brachial plexus injury, or limb ischemia unless explicitly stated otherwise. Consult a board-certified physician before making medical decisions.

References

• Akhlaghpasand M, Tavanaei R, Hosseinpoor M, et al. Safety and potential effects of intrathecal injection of allogeneic human umbilical cord mesenchymal stem cell-derived exosomes in complete subacute spinal cord injury: a first-in-human, single-arm, open-label Phase I clinical trial. Stem Cell Research & Therapy. 2024;15:264. doi:10.1186/s13287-024-03868-0. PubMed
• Bang OY, Kim EH, Cho YH, et al. Circulating extracellular vesicles in stroke patients treated with mesenchymal stem cells: a biomarker analysis of a randomized trial. Stroke. 2022;53(7):2276–2286. doi:10.1161/STROKEAHA.121.036545. PubMed
• Widodo W, Dilogo IH, Kamal AF, et al. Functional outcome and histologic analysis of late-onset total type brachial plexus injury treated with intercostal nerve transfer to median nerve with local umbilical cord-derived mesenchymal stem cells or secretome injection: a double-blinded, randomized controlled study. European Journal of Orthopaedic Surgery & Traumatology. 2024;34(8):4073–4082. doi:10.1007/s00590-024-04110-6. PubMed
• Romanelli P, Bieler LS, Scharler C, et al. Extracellular vesicles can deliver anti-inflammatory and anti-scarring activities of mesenchymal stromal cells after spinal cord injury. Frontiers in Neurology. 2019;10:1225. doi:10.3389/fneur.2019.01225. PubMed
• Doeppner TR, Herz J, Görgens A, et al. Extracellular vesicles improve post-stroke neuroregeneration and prevent postischemic immunosuppression. Stem Cells Translational Medicine. 2015;4(10):1131–1143. doi:10.5966/sctm.2015-0078. PubMed
• Hu GW, Li Q, Niu X, et al. Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells attenuate limb ischemia by promoting angiogenesis in mice. Stem Cell Research & Therapy. 2015;6:10. doi:10.1186/scrt546. PubMed